Compare Novartis AG (NVS) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Star Bulk Carriers Corp — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Star Bulk Carriers Corp trades at $27.66 (market cap $3.17B). The key difference: Novartis AG is far larger — about 94.1× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.62%). Which is the better fit depends on your goals.
| NVS | SBLK | |
|---|---|---|
Market Cap | $298.18B | $3.17B |
Sector | Health | Industrials |
52-Week High | $168.62 | $29.15 |
52-Week Low | $119.31 | $16.79 |
Enterprise Value | $339.50B | $3.65B |
Dividend Yield | 3.02% | 6.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Star Bulk Carriers (SBLK) trades at $28.90, up 1.08% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $1.21 per share, and declared a $0.90 dividend. Fundamentals show robust profitability with a net income margin of 23.87% and a P/E ratio of 11.15, indicating potential value. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though the impact appears neutral.
The outlook for SBLK is positive, driven by strong earnings growth, healthy cash flow, and a favorable analyst consensus with 58.34% buy ratings. Key opportunities include high dividend yields and operational efficiency, while risks involve dry bulk rate volatility and competitive pressures in the shipping sector. Investors should weigh the company's solid financials against industry cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
